Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE ...

A company claiming to be “America’s Largest Ophthalmic Pharmacy” has issued a recall for multiple eye drop products for the ...

In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...

Detailed price information for Kalaris Therapeutics Inc (KLRS-Q) from The Globe and Mail including charting and trades.

NEWTON, Mass.--(BUSINESS WIRE)--#NRTIs--Inflammasome Therapeutics, a private, clinical-stage biotech company developing novel, first-in-class, dual inflammasome inhibitors for prevalent ophthalmic and ...

Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy Inflammasome Therapeutics, a ...

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary ...

Intravitreal drug injection has emerged as a transformative approach in glaucoma management, overcoming the limitations of traditional treatments such as poor compliance with topical medications and ...

Weight loss injections have gained popularity as a quick solution for shedding pounds, but are they safe? We’ll explore the safety, benefits and potential risks associated with weight loss injections ...

Insights on injection technique and the future potential of SCS treatments. Suprachoroidal space (SCS) injection is an exciting method for the targeted delivery of therapies directly adjacent to ...